The mechanisms of cancer immunoescape and development of overcoming strategies

International Journal of Hematology

Volumn 93, Issue 3, 2011, Pages 294-300

  Yaguchi, Tomonori ^a   Sumimoto, Hidetoshi ^a   Kudo Saito, Chie ^a   Tsukamoto, Nobuo ^a   Ueda, Ryo ^a   Iwata Kajihara, Tomoko ^a   Nishio, Hiroshi ^a,b   Kawamura, Naoshi ^a   Kawakami, Yutaka ^a  

^a Division of Cellular Signaling   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer immunotherapy; Cancer stem cell; EMT; Immunosuppression; Mesenchymal stem cell; Oncogenic signal

Indexed keywords

B RAF KINASE INHIBITOR; CYTOKINE; GLYCOPROTEIN GP 100; GSK 2118436; HLA ANTIGEN; IPILIMUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VEMURAFENIB;

ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOESCAPE; CANCER IMMUNOTHERAPY; CANCER TISSUE; CARCINOGENICITY; CELL SUBPOPULATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; SHORT SURVEY; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; NEOPLASM PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 79955829822     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0799-6     Document Type: Short Survey

References (55)

1. Rosenberg SA, Yang JC, et al. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-15. (Pubitemid 39273730)
2. Dudley ME, Yang JC, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-9.
3. Kawakami Y, Fujita T, et al. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci. 2004;95:784-91. (Pubitemid 39545583)
4. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008;27:5869-85.
5. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324:1670-3.
6. Spisek R, Kukreja A, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med. 2007;204:831-40. (Pubitemid 46631612)
7. Ueda R, Ohkusu-Tsukada K, et al. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer. 2009;126:919-29.
8. Wang E, Voiculescu S, et al. Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol. 2006;126:1372-7. (Pubitemid 43997921)
9. Mani SA, Guo W, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-15. (Pubitemid 351636299)
10. Kudo-Saito C, Shirako H, et al. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009;15:195-206.
11. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263-74. (Pubitemid 40488632)
12. Groh V, Wu J, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419:734-8. (Pubitemid 35177960)
13. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467-77. (Pubitemid 351733418)
14. Brahmer JR, Drake CG, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-75.
15. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol. 2008;29:464-8.
16. Tonks A, Hills R, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia. 2007;21:566-8.
17. Ohyama M, Terunuma A, et al. Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest. 2006;116:249-60. (Pubitemid 43121810)
18. Moreaux J, Hose D, et al. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006;108:4194-7. (Pubitemid 44913292)
19. Kawasaki BT, Mistree T, et al. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun. 2007;364:778-82. (Pubitemid 350103695)
20. Sumimoto H, Imabayashi F, et al. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med. 2006;203:1651-6. (Pubitemid 44036269)
21. Yu H, Kortylewski M, et al. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41-51. (Pubitemid 46020826)
22. Petermann KB, Rozenberg GI, et al. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest. 2007;117:3922-9. (Pubitemid 350224101)
23. Kortylewski M, Kujawski M, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11:1314-21. (Pubitemid 41752912)
24. Parsa AT, Waldron JS, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13:84-8. (Pubitemid 46067390)
25. Manicassamy S, Reizis B, et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science. 2010;329:849-53.
26. Ding Y, Shen S, et al. Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells. Nat Med. 2008;14:162-9. (Pubitemid 351214554)
27. Solit DB, Garraway LA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439:358-62. (Pubitemid 43128863)
28. Kefford R, Arkenau H, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol. 2010;28:8503.
29. Flaherty KT, Puzanov I, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-19.
30. Hipp MM, Hilf N, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008;111:5610-20.
31. Ozao-Choy J, Ma G, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69:2514-22.
32. Salama P, Phillips M, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186-92.
33. Udagawa M, Kudo-Saito C, et al. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin Cancer Res. 2006;12:7465-75. (Pubitemid 46095422)
34. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759-67.
35. Hodi FS, O'Day SJ, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711.
36. Curiel TJ, Coukos G, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-9. (Pubitemid 39273735)
37. Yamamoto K, Utsunomiya A, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591-8.
38. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-74.
39. Tsukamoto N, Okada S, et al. Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. Clin Cancer Res. 2009;15:5733-43.
40. Udagawa T, Wood M. Tumor-stromal cell interactions and opportunities for therapeutic intervention. Curr Opin Pharmacol. 2010;10:369-74.
41. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392-401.
42. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res. 2001;264:169-84. (Pubitemid 32989090)
43. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth - bystanders turning into key players. Curr Opin Genet Dev. 2009;19:67-73.
44. Orimo A, Gupta PB, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335-48. (Pubitemid 40692295)
45. Augsten M, Hagglof C, et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA. 2009;106:3414-9.
46. Patocs A, Zhang L, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med. 2007;357:2543-51. (Pubitemid 350294221)
47. Liao D, Luo Y, et al. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune micro-environment in a 4T1 murine breast cancer model. PLoS One. 2009;4:e7965.
48. Mishra PJ, Mishra PJ, et al. Mesenchymal stem cells: flip side of the coin. Cancer Res. 2009;69:1255-8.
49. Kidd S, Spaeth E, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009;27:2614-23.
50. Direkze NC, Hodivala-Dilke K, et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 2004;64:8492-5. (Pubitemid 39552057)
51. Bergfeld SA, DeClerck YA. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 2010;29:249-61.
52. Karnoub AE, Dash AB, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557-63. (Pubitemid 47525152)
53. Uccelli A, Moretta L, et al. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-36.
54. Le Blanc K, Frassoni F, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-86. (Pubitemid 351626841)
55. Djouad F, Bony C, et al. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation. 2006;82:1060-6. (Pubitemid 44632122)